KeyBanc analyst Matthew Mishan initiated coverage of Inspire Medical Systems with an Overweight rating and $287 price target. The analyst sees an "unobstructed growth runway" for the company. Inspire is well positioned to meet or exceed sales growth expectations, due to the low penetration of its approach to addressing obstructive sleep apnea compared with the significant number of potential patients, Mishan tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on INSP:
- Inspire Medical Systems, Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference
- Inspire Medical Systems, Inc. Announces Third Quarter 2022 Financial Results and Updates 2022 Outlook
- TipRanks ‘Perfect 10’ List: These 2 Stocks Tick All the Boxes
Questions or Comments about the article? Write to editor@tipranks.com